<b><a href="investigations.htm" class="texte"><br> <span class="texte"><span class="titre1">Stragen sponsored clinical trials :</span></span><br> <br> Current clinical trials about Myellostat® (homoharringtonine, HHT) Stragen.<br> </a></b><a href="trials/trial01.htm" class="texte">Phase I-II trial to asses the dose limiting toxicity, tolerance and efficacy of hemi-synthetic homoharringtonine (Myelostat®) in combination with imatinib mesylate (Glivec®) in patients with chronic myeloid leukemia after cytogenetic failure with Glivec®.</a><span class="texte"><i><br> Investigator Coordinator : Prof F. Guilhot CHU Poitiers France</i></span> <br> <br> <a href="trials/trial02.htm" class="texte">A phase II multicentre, single-arm, open-label study of subcutaneous hemi-synthetic homoharringtonine (HHT) alone in patients with accelerated phase chronic myeloid leukemia (CML) who are refractory to, or have relapsed on imatinib mesylate</a><span class="texte"><br> <i>Protocol : HHT-CML/INTL/04.2<br> Investigator Coordinator : Dr Frederic Maloisel CHU Strasbourg France - Dr David Marin, Hammersmith Hospital, London UK</i></span><br> <br> <span class="titre1">Investigators’ ongoing clinical trials:</span><span class="texte"></span><br> <br> <span class="texte">Semi-synthetic homoharringtonine (Myelostat©) for CML patients in accelerated phase after imatinib failure.<br> <i>Contact: Dr David Marin - Catherine Lewis Centre - Hammersmith Hospital, Du Cane Road, London W12 0HS)</i></span><br> <br> Semi-synthetic homoharringtonine (Myelostat©) in combination with imatinib for CML patients who have achieved partial or complete cytogenetic responses.<br> <i>Contact: Dr David Marin - Catherine Lewis Centre - Hammersmith Hospital, Du Cane Road, London W12 0HS)</i><br>
About Stragen
|
Contact
|
Sitemap
|
Legal Notices
© 2005
Stragen
Pharma SA - All rights reserved
